Literature DB >> 19133295

Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: evaluation in a measles encephalitis model.

H Jeulin1, V Venard, D Carapito, C Finance, F Kedzierewicz.   

Abstract

Ribavirin (RBV) is a water-soluble synthetic nucleoside with broad spectrum antiviral properties, but it is ineffective against major viral encephalitis because of a failure to cross the blood-brain barrier (BBB). The antiviral activity of the complex ribavirin/alpha-cyclodextrin was previously demonstrated to be stronger than free ribavirin, in an in vivo model of measles virus (MV) encephalitis in mice. The role of cyclodextrin (CD) on ribavirin uptake into the brain needs to be defined. Ribavirin specific extraction from brain tissue was developed, based on a solid phase extraction. It was quantified by high performance liquid chromatography at different time points after intraperitoneal injection of single or multiple doses of free ribavirin or of the complex ribavirin/alpha-cyclodextrin. Whatever the tested dose (40 or 100mg/kg), the amount of ribavirin in the brain was significantly higher (p<0.001) when the drug was injected as a complex with alpha-cyclodextrin, in healthy or measles virus-infected mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19133295     DOI: 10.1016/j.antiviral.2008.12.006

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

Review 1.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

2.  Measles Virus Bearing Measles Inclusion Body Encephalitis-Derived Fusion Protein Is Pathogenic after Infection via the Respiratory Route.

Authors:  Cyrille Mathieu; Marion Ferren; Eric Jurgens; Claire Dumont; Ksenia Rybkina; Olivia Harder; Debora Stelitano; Silvia Madeddu; Giuseppina Sanna; Dayna Schwartz; Sudipta Biswas; Diana Hardie; Takao Hashiguchi; Anne Moscona; Branka Horvat; Stefan Niewiesk; Matteo Porotto
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

3.  Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Authors:  F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

4.  Enhancing both oral bioavailability and brain penetration of puerarin using borneol in combination with preparation technologies.

Authors:  Tao Yi; Dandan Tang; Fan Wang; Jiqiong Zhang; Jiao Zhang; Jirui Wang; Xiaoyu Xu; Jifen Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 5.  Measles virus infection of the CNS: human disease, animal models, and approaches to therapy.

Authors:  Dajana Reuter; Jürgen Schneider-Schaulies
Journal:  Med Microbiol Immunol       Date:  2010-08       Impact factor: 4.148

Review 6.  Enterovirus infections of the central nervous system.

Authors:  Ross E Rhoades; Jenna M Tabor-Godwin; Ginger Tsueng; Ralph Feuer
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

7.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

8.  Low-dose ribavirin treatments attenuate neuroinflammatory activation of BV-2 Cells by interfering with inducible nitric oxide synthase.

Authors:  Iva Bozic; Danijela Savic; Marija Jovanovic; Ivana Bjelobaba; Danijela Laketa; Nadezda Nedeljkovic; Mirjana Stojiljkovic; Sanja Pekovic; Irena Lavrnja
Journal:  Anal Cell Pathol (Amst)       Date:  2015-08-27       Impact factor: 2.916

9.  In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates.

Authors:  Alessandro Giuliani; Anna Giulia Balducci; Elisa Zironi; Gaia Colombo; Fabrizio Bortolotti; Luca Lorenzini; Viola Galligioni; Giampiero Pagliuca; Alessandra Scagliarini; Laura Calzà; Fabio Sonvico
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 10.  Antivirals in medical biodefense.

Authors:  J J Bugert; F Hucke; P Zanetta; M Bassetto; A Brancale
Journal:  Virus Genes       Date:  2020-02-19       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.